Bionumerik reports data on two novel supercomputer engineered antican...( ased on historical studies of patients ...)

ased on historical studies of patients who were treated with the same chemotherapy drugs without BNP7787. These results also appear to indicate that while the toxic side effects of cisplatin and paclitaxel are alleviated , the tumor specific programmed cell death (apoptosis) associated with this therapy remains intact.

The Company plans to initiate Phase 3 trials later this year for BNP7787 which has been granted U.S. Food and Drug Administration "Fast Track" designation for the prevention or reduction of the nerve damage associated with paclitaxel.

Karenitecin
Additional data presented at AACR further indicates that BioNumerik's goal of being the first to discover, synthesize, formulate, patent and develop a new class of silicon containing semisynthetic camptothecins has been accomplished. Karenitecin BNP1350 is a member of a novel class of specifically developed lipophilic camptothecins. Antitumor activity of BNP1350 has been confirmed in in vitro models of human prostate, breast, lung, colon, melanoma, glioblastoma and ovarian cancer cell lines. Experimental observations suggest the presence of a BNP1350 dimer complex that is believed to be responsible for protecting a key chemical "lactone ring" on the camptothecin molecule. These findings were confirmed in the ongoing Phase 1 study where an impressive 90% or greater lactone ring stability has been measured in patients receiving doses ranging from 0.15- 1.2mg/m2 daily times five days of karenitecin.

Based on these encouraging results and scientific findings, BioNumerik is planning to proceed with Phase 2 clinical trials in gliomas and lung cancer later this year. Additionally, a pediatric Phase 1 study has been initiated and an oral formulation of karenitecin BNP1350 is expected to be introduced into the clinic in the coming months.

'"/>

Contact: Page Sargisson
p.sargisson@noonanrusso.com
415-677-4455 x 229
Noonan/Russo Communications
5-Apr-2000

Page: 1 2
Related biology news :

1. APP reports Abraxane(TM) is active in breast cancer patients who failed taxol or taxotere
2. Scientists question reports of massive ant supercolonies in California and Europe
3. Survey reports fall in stem cell transplants for breast cancer
4. VaxGen reports Phase I clinical trial results of anthrax vaccine candidate
5. Immerge reports PERVs most infectious to human cells not part of germ-line DNA of mini-swine
6. By the year 2050, human population could add 2.6 billion people, reports Rockefeller scientist
7. Measles on the rise as vaccinations fall in the UK, Science study reports
8. WCS biologist George Schaller reports surprising increase in Tibets wildlife
9. Clinical study reports findings of combination therapy with DOXIL
10. Europes population has developed new tendency to shrink, Science study reports
11. U of A scientist finds Atlantic salmon escapes higher than government reports